Business
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of
About this update from Annexon, Inc.
BRISBANE, Calif. , April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love , Esq., president and chief executive officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 11:45 a.m. ET . A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com . A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. About Annexon Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to millions of patients to help them live their best lives. To learn more visit annexonbio.com . Investor Contact: Joyce Allaire LifeSci Advisors [email protected] Media Contact: Beth Keshishian 917-912-7195 [email protected] Source: Annexon Biosciences